Takeda invest €36 million in Grange Castle facility
By William O'Connor
AN INVESTMENT of €36 million has been announced today by biopharmaceutical company Takeda at its facility in Clondalkin to address growing global demand.
Located in Grange Castle Business Park, the investment will support the expansion of the company’s cell therapy production facility and create approximately 100 new jobs over the next three years.
The Takeda facility in Grange Castle
The commercial scale cell therapy production facility is the first of its kind in Ireland. Following the expansion, the Grange Castle site will play an important role in supplying European, US and Canadian markets with a cell therapy treatment option for patients.
Commenting on the announcement An Tánaiste and Minister for Enterprise, Trade and Employment, Leo Varadkar, TD, said: “I’m really pleased Takeda Ireland is expanding in Grange Castle, creating 100 jobs over the next three years.
“Our highly skilled workforce is just one of the reasons why Ireland is recognised as a global hub for biopharmaceutical companies like Takeda. I wish them every success with their expansion plans.”
Thomas Wozniewski, Takeda Global Manufacturing & Supply Officer: commented: “The investment to expand this state-of-the-art cell therapy production facility highlights the importance of cell therapy for Takeda.
“The expansion of the cell therapy manufacturing line in Grange Castle will help us to serve more patients worldwide, and it underlines our commitment to Ireland as a key country. With its advanced use of digital technologies, the cell therapy manufacturing lines in Grange Castle are a testimony to our innovation capabilities.”
Paul Keogh, Grange Castle Site Head, commented: “Since beginning operations in 2007, the Grange Castle site has grown from strength to strength thanks to a great team and strong investment in our people and technology.
“The investment announced today further highlights Grange Castle as a trusted manufacturing site in the network and that’s something we are very proud of.”
Takeda is a global, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments.
Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Haematology, Neuroscience, and Gastroenterology (GI).
The company makes targeted R&D investments in Plasma-Derived Therapies and Vaccines.
By subscribing to The Echo you are supporting your local newspaper Click Here: Echo Online.
TAGS Latest
